Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 4, 1998, Pages 309-317

  Wan, Margaret S K ^a   Fell, Patricia L ^a   Akhtar, Saghir ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HAMMERHEAD RIBOZYME; RIBONUCLEOPROTEIN; RIBONUCLEOTIDE; RIBOZYME; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIVISION; CELL IMMORTALIZATION; CELL LYSATE; CHROMOSOME SIZE; CONTROLLED STUDY; DNA REPLICATION; DNA SEQUENCE; DNA SYNTHESIS; DOSE RESPONSE; DRUG SYNTHESIS; ENZYME INHIBITION; GENE AMPLIFICATION; GENE TARGETING; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA CLEAVAGE; SENESCENCE; TUMOR CELL; TUMOR GROWTH;

EID: 0031686224     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.309     Document Type: Article

References (14)

1. AKHTAR, S. (1998). Antisense technology: Selection and delivery of optimally acting antisense oligonucleotides. J. Drug Targeting 5, 225-234.
2. BEIGELMAN, L., MCSWIGGEN, J., DRAPER, K., GONZALEZ, C., JENSEN, K., KARPEISKY, A., MODAK, A., MATULICADAMIC, J., DIRENZO, A., HAEBERLI, P., SWEEDLER, D., TRACZ, D., GRIMMS, S., WINCOTT, F., THACKRAY, V., and USMAN, N. (1995). Chemical modification of hammerhead ribozymes. J. Biol. Chem. 270, 25701-25708.
3. BLASCO, M.A., LEE, H.-W., HANDE, M.P., SAMPER, E., LANSDORP, P.M., DEPINHO, R.A., and GREIDER, C.W. (1997). Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34.
4. BODNAR, A.G., OUELLETTE, M., FROLKIS, M., HOLT, S.E., CHIU, C.-P., MORIN, G.B., HARLEY, C.B., SHAY, J.W., LICHSTEINER, S., and WRIGHT, W.E. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352.
5. BROCCOLI, D., YOUNG, J.W., and DE LANGE, T. (1995). Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA 92, 9082-9086.
6. BRYAN, T.M., ENGLEZOU, A., DALLA-POZZA, L., DUNHAM, M.A. and REDDEL, R.R. (1997). Evidence for an alternative mechanism for telomere length in human tumours and tumour derived cell lines. Nat. Med. 3, 1271-1274.
7. BURGER, A.M., BIBBY, M.C., and DOUBLE, J.A. (1997a). Telomerase activity in normal and malignant mammalian tissues: Feasibility of telomerase as a target for cancer chemotherapy. Br. J. Cancer 75, 516-522.
8. BURGER, A.M., DOUBLE, J.A., and NEWELL, D.R. (1997b). Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer [A] 33, 638-644.
9. COULSON, J.M., POYNER, D.R., CHANTRY, A., IRWIN, W.J., and AKHTAR, S. (1996). A non-antisense sequence-selective effect of a phosphorothioate oligonucleotide targeted to EGFR in A431 cells. Mol. Pharmacol. 50, 314-325.
10. DELANGE, T. (1998). Telomeres and senescence: Ending the debate. Science 279, 334-335.
11. ELKINS, D.A., and ROSSI, J.J. (1995). Cellular delivery of ribozymes. In: Delivery Strategies for Antisense Oligonucleotide Therapeutics. S. Akhtar, ed. (CRC Press, Boca Raton, FL).
12. SHAY, J.W. (1997). Telomerase in development and cancer. J. Cell Physiol. 173, 266-270.
13. SUN, D.Y., THOMPSON, B., CATHERS, B.E., SALAZAR, M., KERWIN, S.M., TRENT, J.O., JENKINS, T.C., NEIDLE, S., and HURLEY, L.H. (1997). Inhibition of human telomerase by a G-quadraplex-interactive compound. J. Med. Chem. 40, 2113-2116.
14. SYMONS, R.H. (1992). Small catalytic RNAs. Annu. Rev. Biochem. 61, 641-671.